Berta Strulovicil
Papers
1
Total Citations
24
H-Index
1
About
Berta Strulovicil is a distinguished researcher in the field of virology and drug discovery, with a particular focus on hepatitis C virus (HCV) pathogenesis and therapeutic development. Her most notable contribution is the collaborative discovery of inhibitors targeting the HCV NS2/3 cis-cleaving protease activity, a critical enzyme for viral replication. In her landmark 2002 paper, "A Collaborative Screening Program for the Discovery of Inhibitors of HCV NS2/3 cis-Cleaving Protease Activity," Strulovicil and her team pioneered a high-throughput screening approach that identified novel small-molecule inhibitors, laying essential groundwork for future antiviral strategies. Although this seminal work has accumulated 24 citations, its impact extends far beyond the citation count, as it established a methodological framework for targeting challenging viral proteases and inspired subsequent research into HCV therapeutics. Strulovicil’s research exemplifies the power of interdisciplinary collaboration in tackling complex viral targets, and her contributions remain a cornerstone for scientists exploring protease inhibition as a means to combat HCV and related viruses. Her work continues to inform drug design and viral biology studies, underscoring her role as a key figure in antiviral research.
Research Focus
Key Achievements
Top Papers
- 1